Figure S2 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism

MLA

Céleste Lebbe, et al. Figure S2 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22480554.

APA

Céleste Lebbe, Samia Mourah, Maxime Battistella, Keyvan Rezai, Samuel Huguet, Annick Tibi, Didier Bouton, Paul Vilquin, Zineb Ghrieb, Fanélie Jouenne, Aurélie Sadoux, Coralie Reger de Moura, Caroline Dutriaux, Mona Amini-Adle, Julie Delyon, Barouyr Baroudjian, Marc Pracht, Laetitia Da Meda, Thierry Lesimple, … Baptiste Louveau. (2023). Figure S2 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. https://doi.org/10.1158/1078-0432.22480554

Chicago

Céleste Lebbe, Samia Mourah, Maxime Battistella, Keyvan Rezai, Samuel Huguet, Annick Tibi, Didier Bouton, et al. 2023. “Figure S2 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism,” March. doi:10.1158/1078-0432.22480554.